Lincomycin hydrochloride hydrate (Lincomycin hydrochloride monohydrate)
(Synonyms: 林可霉素) 目录号 : GC32242
A lincosamide antibiotic
Cas No.:7179-49-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Lincomycin is a lincosamide antibiotic originally isolated from S. lincolnensis.1,2 It is active against Gram-positive bacteria, including various strains of S. aureus, S. epidermidis, S. pneumoniae, and S. pyogenes (MICs = 0.2-3.2, 0.4-1.8, 0.01-0.8, and 0.04-0.8 ?g/ml, respectively).2 Lincomycin selectively inhibits protein synthesis in purified ribosomes from S. aureus over E. coli (IC50s = 0.03 and 1.7 ?g/ml, respectively, in cell-free assays).3 It is protective against development of mastitis in a mouse model of acute mastitis induced by S. aureus with a 50% protective dose (PD50) value of 3.5 mg/kg.4 Formulations containing lincomycin have been used in the treatment of Gram-positive bacterial infections.
1.Wilson, D.N.The A-Z of bacterial translation inhibitorsCrit. Rev. Biochem. Mol. Biol.44(6)393-433(2009) 2.Spí?ek, J., and ?ezanka, T.Lincomycin, clindamycin and their applicationsAppl. Microbiol. Biotechnol.64(4)455-464(2004) 3.Matzov, D., Eyal, Z., Benhamou, R., et al.Structural insights of lincosamides targeting the ribosome of Staphylococcus aureusNucleic Acids Res.45(17)10284-10292(2017) 4.Yancey, R.J., Jr., Kinney, M.L., and Ford, C.W.Efficacy of lincosaminide antibiotics in the treatment of experimental staphylococcal mastitis in lactating miceJ. Antimicrob. Chemother.15(2)219-232(1985)
| Cas No. | 7179-49-9 | SDF | |
| 别名 | 林可霉素 | ||
| Canonical SMILES | C[C@@H](O)[C@](NC([C@H]1N(C)C[C@H](CCC)C1)=O)([H])[C@@]2([H])O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O.Cl.O | ||
| 分子式 | C18H37ClN2O7S | 分子量 | 461.01 |
| 溶解度 | DMSO : ≥ 100 mg/mL (216.92 mM);Water : 50 mg/mL (108.46 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1692 mL | 10.8458 mL | 21.6915 mL |
| 5 mM | 0.4338 mL | 2.1692 mL | 4.3383 mL |
| 10 mM | 0.2169 mL | 1.0846 mL | 2.1692 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Clindamycin hydrochloride monohydrate and its ethanol solvate
Acta Crystallogr C 2010 Feb;66(Pt 2):o97-100.PMID:20124689DOI:10.1107/S0108270110000958.
Clindamycin hydrochloride, an antibiotic of the Lincomycin family, was crystallized as the monohydrate, namely (2S,4R)-2-(N-{(1S,2S)-2-chloro-1-[(3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylsulfanyl)perhydropyran-2-yl]propyl}aminocarbonyl)-4-propylpyrrolidinium chloride monohydrate, C(18)H(34)ClN(2)O(5)S(+).Cl(-).H(2)O, (I), and as the monohydrate ethanol solvate, C(18)H(34)ClN(2)O(5)S(+).Cl(-).H(2)O.C(2)H(6)O, (II). The conformation of the clindamycin molecule in both crystal structures is the same and is found to be similar to that in enzyme-bound clindamycin. The simultaneous presence of free chloride ions and water molecules in (I) and of additional ethanol molecules in (II) provides an interesting network of hydrogen bonds. The significance of this study lies in the interactions in these structures and the aggregations occurring via hydrogen bonds in the hydrated and solvated crystalline forms of the title compound.
Role of interlayer hydration in Lincomycin sorption by smectite clays
Environ Sci Technol 2009 Aug 15;43(16):6171-6.PMID:19746709DOI:10.1021/es900760m.
Lincomycin, an antibiotic widely administered as a veterinary medicine, is frequently detected in water. Little is known about the soil-water distribution of Lincomycin despite the fact that this is a major determinant of its environmental fate and potential for exposure. Cation exchange was found to be the primary mechanism responsible for Lincomycin sorption by soil clay minerals. This was evidenced by pH-dependent sorption, and competition with inorganic cations for sorptive sites. As solution pH increased, Lincomycin sorption decreased. The extent of reduction was consistent with the decrease in cationic Lincomycin species in solution. The presence of Ca2+ in solution diminished Lincomycin sorption. Clay interlayer hydration status strongly influenced Lincomycin adsorption. Smectites with the charge deficit from isomorphic substitution in tetrahedral layers (i.e., saponite) manifest a less hydrated interlayer environment resulting in greater sorption than that by octahedrally substituted clays (i.e., montmorillonite). Strongly hydrated exchangeable cations resulted in a more hydrated clay interlayer environment reducing sorption in the order of Ca- < K- < Cs-smectite. X-ray diffraction revealed that Lincomycin was intercalated in smectite clay interlayers. Sorption capacity was limited by clay surface area rather than by cation exchange capacity. Smectite interlayer hydration was shown to be a major, yet previously unrecognized, factor influencing the cation exchange process of Lincomycin on aluminosilicate mineral surfaces.
Evaluating the effect of aminoglycosides on the interaction between bovine serum albumins by atomic force microscopy
Int J Biol Macromol 2019 Aug 1;134:28-35.PMID:31063788DOI:10.1016/j.ijbiomac.2019.05.008.
Characterization and determination of protein-protein interactions (PPIs) plays an important role in molecular biological science. In this study, the effect of aminoglycosides (AGs: streptomycin, gentamycin, Lincomycin and clindamycin) on interactions between bovine serum albumin (BSA) was evaluated employing imaging and probing adhesion event by AFM. Multi-spectroscopy and molecular docking were supplementary to investigate the acting forces of the effect. AFM measurements revealed the aggregation of BSA grains and changes of adhesion forces at single molecule level. With adhesion forces between BSA pairs decomposed by Poisson method, specific forces in streptomycin, gentamycin, Lincomycin and climdamycin were obviously decreased with the rate of 33.1%, 26.4%, 32.3% and 31.3% while non-specific forces slightly decreased with 5.5%, 3.3%, 4.0% and 7.7%. Combined with results of multi-spectroscopy as well as molecular docking, the whole determination showed AGs affected PPIs by multiple forces, where the hydrogen bonding and hydration effect were the main reasons. The binding of drugs and proteins acted by hydrogen bonding affected the interaction forces between BSA. Consequently, AFM was proposed to be an effective and precise tool in application including evaluating the effects of exogenous compounds on biomacromolecular interactions and rapid screening of drug candidates to avoid potential damages in disease treatment.